Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity

Morris MW1, Stewart SA2, Heisler C3, Sandborn WJ4, Loftus EV5, Zello GA1, Fowler SA1, Jones JL2. Inflamm Bowel Dis. 2018 Jan 18;24(2):277-285. doi: 10.1093/ibd/izx018.

Author information

1 University of Saskatchewan, Saskatoon, SK, Canada.

2 Dalhousie University, Halifax, NS, Canada.

3 Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.

4 University of California, San Diego, San Diego, California.

5 Mayo Clinic, Rochester, Minnesota.


BACKGROUND: The Crohn's Disease Activity Index (CDAI), a scoring index including patient-reported outcomes (PROs), has known limitations for measuring intestinal inflammatory disease burden. Noninvasive markers of inflammation could prove more accurate than PROs; thus, regulatory authorities are exploring the use of PROs and endoscopic data as coprimary end points in clinical trials. The aim of this study was to assess the predictive ability of individual components of the CDAI, along with biomarker concentrations, to create models for predicting endoscopic disease activity.

METHODS: Between 2004 and 2006, 164 patients with established Crohn's disease (CD) undergoing clinically indicated ileocolonoscopy were recruited. Individual CDAI variables and fecal calprotectin (FC) were selected to explore their predictive accuracy for endoscopic disease activity, with the Simple Endoscopic Score-Crohn's Disease (SES-CD) as the outcome variable. Simple Poisson regression was performed on each variable, and 2 multivariate models were created (PRO-exclusive and PRO+FC [PRO+]). Additional analyses explored the patient-level agreement between models.

RESULTS: Number of liquid stools, abdominal pain, hematocrit (Hct), FC, and high-sensitivity C-reactive protein (hsCRP) correlated significantly with the SES-CD. For the prediction of SES-CD (>7 vs ≤6), the area under the curve (AUC) was 0.81, with 63% and 88% sensitivity and specificity, for the PRO+ model, compared with a 0.56 AUC, with 61% and 55%, respectively, for the PRO model. Intra-individual comparison revealed the PRO+ model to be superior in the prediction of endoscopically active disease.

CONCLUSIONS: The inclusion of biomarkers significantly improved predictive accuracy for endoscopic diseaseactivity compared with PRO-exclusive models.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.